Notícias e Atividades da Actinium Pharmaceuticals

Actinium Pharmaceuticals é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Actinium Pharmaceuticals é uma empresa listada sob o símbolo ATNM (US).

Veja o organograma con seus 18 executivos principais

Biografias mais buscadas da Actinium Pharmaceuticals

• Sandesh Seth, Chairman of the Board and Chief Executive Officer
• David Nicholson, Lead Independent Director
• Richard Steinhart, Director

Recentes movimentos de executivos em Actinium Pharmaceuticals

• June Almenoff, ingressou na Companhia como Director  (Notícia publicada em 5 de novembro de 2024).

Criar um alerta
para seguir os movimentos de executivos da Actinium Pharmaceuticals.

Actinium Pharmaceuticals possui 1.834 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Eli Lilly (Estados Unidos).

Popular M&A news in Farmacêutica

• Imbria Pharmaceuticals acaba de anunciar uma arrecadação de fundos de 58 milhões de dólares. (publicado em 10 de abril de 2025).
• Clario adquiriu NRx Pharmaceuticals (publicado em 18 de março de 2025).
• Knight Therapeutics has announced the acquisition of Paladin Labs  (publicado em 12 de março de 2025).

Outros contatos sugeridos na indústria do Farmacêutica

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets da Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer da Adare Pharmaceuticals
• Seth Harrison - Chairman and Director da Braeburn Pharmaceuticals

Saiba mais sobre a indústria do Farmacêutica

Últimos comunicados de imprensa de Actinium Pharmaceuticals

• Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225 :: Actinium Pharmaceuticals, Inc. (ATNM)
• Actinium Pharmaceuticals to Present Business Update at Trump Mar-A-Lago Club Today :: Actinium Pharmaceuticals, Inc. (ATNM)
• Press Releases :: Actinium Pharmaceuticals, Inc. (ATNM)
• Actinium Pharmaceuticals Provides Business Update After Presentation at Trump Mar-A-Lago Club Announcing Novel Non-PSMA Prostate Cancer Radiotherapy ATNM-400 and Outlining Revitalized Clinical Pipeline with 2025 Corporate Objectives :: Actinium Pharmaceut
• Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities :: Actinium Pharmaceuticals, Inc. (ATNM)
• Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program :: Actinium Pharmaceuticals, Inc. (ATNM)
• Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical
• Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy :: Actinium Pharmaceuticals, Inc. (ATNM)
• Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO® :: Actinium Pharmaceuticals, Inc. (ATNM)
• Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia :: Actinium Pharmaceuticals, Inc. (ATNM)
• View more press releases Close

Redes sociais sobre Actinium Pharmaceuticals

• Actinium Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
• Actinium Pharmaceuticals na LinkedIn, Twitter e YouTube